Physicochemical characterization and phase I study of CMAB008, an infliximab biosimilar produced by a different expression system

BACKGROUND: Infliximab (Remicade), a chimeric monoclonal antibody against human TNFα, will inevitably face competition from biosimilar products, because of its effectiveness in autoimmune diseases and rapidly increasing market demand. According to guidelines for biosimilar development, the “biosimil...

Descripción completa

Detalles Bibliográficos
Autores principales: An, Qing, Zheng, Yingxin, Zhao, Yirong, Liu, Tao, Guo, Huaizu, Zhang, Dapeng, Qian, Weizhu, Wang, Hao, Guo, Yajun, Hou, Sheng, Li, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6420106/
https://www.ncbi.nlm.nih.gov/pubmed/30880912
http://dx.doi.org/10.2147/DDDT.S170913

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6420106/
https://www.ncbi.nlm.nih.gov/pubmed/30880912
http://dx.doi.org/10.2147/DDDT.S170913

Ejemplares similares